Sermorelin Satisfaction Trends Over Time: What Real Users and Clinical Data Actually Show
HealthRX.com
Trials measured growth and hormones, not satisfaction over time
See the public record for Sermorelin
At a glance
- What it is / a 29-amino-acid GHRH analogue, not growth hormone [4]
- Approval status / Geref, discontinued 2008; approvals withdrawn 2009 [5]
- Sold today as / a compounded product, not FDA-approved [6]
- Trial follow-up / 110 children treated for up to 1 year; a review also describes limited data from a few children after 36 months [1][4]
- Height velocity in that trial / 4.1 to 8.0 to 7.2 cm/yr [1]
- Adult trials / 14 days and 6 weeks [2][3]
Is there published data on satisfaction over time?
The trials described on this page report growth, hormone and body-composition outcomes, not satisfaction. Online reviews may describe changes over time, but these studies do not establish when people begin to feel a benefit or when any perceived benefit peaks.
Sermorelin prompts the pituitary to release the body's own growth hormone; it is not growth hormone [4]. In 30 healthy men aged 19 to 43, an intravenous dose cleared quickly yet growth hormone stayed raised for about 3 hours [7].
What people on Reddit report
Two firsthand replies in one forum thread asking whether sermorelin is worth using. They disagree on whether it works given time.
It's a gentle GHRH, good sleep, can work if you give it time to support better recovery and muscle growth.Read the source discussion
No hype it sucks. There are multiple peptides that are way better and do the same thing. SERM is old, the newer ones are way better. Ipamorelin, cjc-1295, TesamorelinRead the source discussion
The one-year trial measured height
An open-label, multicenter study enrolled 110 previously untreated prepubertal children with growth hormone deficiency, 86 evaluable, given 30 micrograms per kg subcutaneously at bedtime for up to 1 year [1]. Height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months [1]. Height velocity, bone age and safety measures were monitored every 3 to 6 months; satisfaction was not among the listed outcome measures [1]. A review of sermorelin in these children notes limited data suggesting the height-velocity effect was maintained for 36 months of continued treatment in a few children [4].
The adult studies were short
Ten healthy men with a mean age of 68 took 0.5 mg and 1 mg of GHRH(1-29) twice daily for 14 days each, in random order, compared with nine men aged about 26; at 1 mg, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [2].
Eleven men aged 64 to 76 self-injected 2 mg nightly for 6 weeks; nocturnal growth hormone rose, and two of six strength measures and an abdominal-crunch endurance test improved, but IGF-I and DEXA measures of muscle and fat did not change [3].
Those were study doses, not current approved doses [1][2][3]. The adult studies lasted 14 days and 6 weeks, so they did not evaluate outcomes beyond those periods [2][3].
Tolerability and approval status
In the 1-year pediatric study, no adverse changes appeared in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [1].
Geref held the only sermorelin approvals: a 0.05 mg diagnostic product (1990) and 0.5 mg and 1 mg vials for growth failure in children with idiopathic growth hormone deficiency (1997) [5]. The maker discontinued both in 2008 and asked FDA to withdraw the applications; approval ended June 18, 2009, and in 2013 FDA determined Geref was not withdrawn for safety or effectiveness reasons [5]. Sermorelin sold in the US now is compounded, and compounded drugs are not FDA-approved [6].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Did any trial measure how people felt on sermorelin?
How quickly did the trials show changes?
Is sermorelin FDA-approved today?
References
Show all 8 referencesHide references
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Federal Register :: Request Access.
- Official web page.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- Reddit participants. What's the hype on sermorelin? (r/PeptideForum). Accessed 2026-11-11.